Search
Nov 21, 2024
The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta
Vir Chief Medical Officer Mark Eisner discusses the MARCH Phase 2 study results for hepaitis B, and Hôpital Beaujon Professor of...
Dec 5, 2023
Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future
Vir's new CEO gives an overview of the company's programs and discusses future plans to expand into autoimmune disease and oncology.